In contrast to sorafenib, the FLT3 inhibitors midostaurin and gilteritinib have both been investigated in prospective trials for relapsed/refractory FLT3-mutated AML that enrolled post-allo-HCT relapse patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.